Two Factors Why Congress is Boosting Biotech

January 06 00:41 2017

As indicated by the iShares Nasdaq Biotechnology Index (IBB), the biotechnology sector has begun to see a huge bump in attention now that President-elect Donald Trump is set to take office in January. But that’s not the only factor, President Barack Obama has also sparked attention as the approval of a new bill could give a large infusion of cash to companies in the space.

The U.S. Senate approved complex health care legislation earlier this month. The bill, $6.3 billion legislation known as the 21st Century Cures Act, is designed to provide funding for things like cancer research, the epidemic of opioid abuse, mental health treatment initiatives and what may be most important is that it helps the Food and Drug Administration (FDA) speed up drug approvals to push for better technology in medicine overall.

One company benefiting from the recent bump in biotech activity is Propanc Health Group (PPCH).  The company has climbed over a penny a share since the beginning of December, and is setting up itself up to head into the New Year with some bullish momentum.

Part of what sparked the increased interest in PPCH is there recent presentation at the LD Microcap Conference which is one of, if not the largest microcap conference of the year.

This kind of reaction after the presentation is a great sign for the company.  If you’d like to see a presentation on PPCH, the company also presented at a Virtual Investor Conference.  Propanc’s presentation will be available 24/7 for 90 days. Investors and advisors may download shareholder materials from the “virtual trade booth” for the next three weeks.  It is all available at this link: http://tinyurl.com/1201postpr

To view the new Propanc video “Mechanism of Action” on anti-cancer product candidate, PRP, please click on the following link: http://www.propanc.com/news-media/video

PPCH completed a 28 day toxicokinetic study in rats to measure the bio-distribution of their lead product, PRP, in relation to its toxicity over time.  Based on the positive results from the study, the Company announced commencement of a Good Laboratory Practice (GLP) Compliant 28 day repeat dose toxicity study in rats.  Once this pivotal study is completed, data will be used to support a clinical trial application in the UK, in 2017.

They’ve also executed a contract manufacturing agreement with AmatsiQBiologicals, based in Gent, Belgium. The agreement covers the development and GMP (Good Manufacturing Practice) production of certain enzymes for development purposes, including but not limited to first-in-man studies for the Company’s lead product, PRP.

If you’re looking to benefit from this increased interest in biotech, PPCH, looks like one of the more high potential opportunities there is for investors.

Along with PPCH, there are a few other biotech companies worth taking a strong look at:

Egalet Corp. (EGLT) as the Company announced on December 16, 2016, positive top-line results from a Category 3 intranasal human abuse potential (HAP) study of Egalet-002, an abuse-deterrent, extended-release oxycodone product candidate. EGLT

BioCryst Pharmaceuticals, Inc. (BCRX) has had a nice December so far.  JMP Securities recently upgraded BioCryst to Market Outperform from previously downgrading the stock to Market Perform back in August. To further support the rating, BioCryst shares have increased by as much as 62% since early November. The company’s Rapivab has been fully approved and commercialized for the treatment of acute uncomplicated influenza in patients 18 and older.

Cytori Therapeutics, Inc. (CYTX) recently announced that it has surpassed the 50 percent enrolment milestone for its ADRESU trial in Japan. “ADRESU is a late phase, investigator-initiated Japanese clinical trial to study the efficacy and safety of Cytori Cell Therapy in men with stress urinary incontinence after prostatic intervention for prostate cancer or benign prostatic hypertrophy.” Cytori wrote in their recent news release.

Sangamo Biosciences, Inc. (SGMO) recently presented preclinical and manufacturing data that support SB-525, its gene therapy program for hemophilia A, at the 58th Annual Meeting of the American Society of Hematology (ASH) in San Diego.  Since the presentation, SGMO has been on a bit of a run.

Legal Disclaimer

Except for the historical information presented herein, matters discussed in this article contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. ACR Communication, LLC. which owns Microcapspeculators.com, is not registered with any financial or securities regulatory authority, and does not provide nor claims to provide investment advice or recommendations to readers of this release. ACR Communication, LLC. which owns, Microcapspeculators.com may from time to time have a position in the securities mentioned herein and may increase or decrease such positions without notice. For making specific investment decisions, readers should seek their own advice. ACR Communication LLC. which owns Microcapspeculators.com may be compensated for its services in the form of cash-based compensation or in equity in the companies it writes about, or a combination of the two. For Full Legal Disclaimer Click Here.

Media Contact
Company Name: Microcap Speculators
Contact Person: Media Manager
Email: [email protected]
Phone: 1-702-720-6310
Country: United States
Website: http://microcapspeculators.com/

  Categories: